Tianyu Qin,Gang Chen. Recent advances in targeted therapy for ovarian cancer. Oncol Transl Med, 2022, 8: 28-35.
Recent advances in targeted therapy for ovarian cancer
Received:February 07, 2022  Revised:March 09, 2022
View Full Text  View/Add Comment  Download reader
KeyWord:ovarian cancer; targeted therapy; anti-angiogenesis; poly-(ADP)-ribose polymerase (PARP) inhibitor; immune checkpoint inhibitor (ICI); clinical trial
Author NameAffiliationPostcode
Tianyu Qin National Clinical Research Center for Gynecology and Obstetrics
Cancer Biology Research Center
Department of Gynecology and Obstetrics
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China 
430030
Gang Chen National Clinical Research Center for Gynecology and Obstetrics
Cancer Biology Research Center
Department of Gynecology and Obstetrics
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China 
430030
Hits: 2797
Download times: 3331
Abstract:
      The global burden of ovarian cancer is gradually increasing while patients still suffer from relatively limited treatment options. With recent advances in the decoding of the molecular landscape of ovarian cancer, more options in targeted strategy were offered and can therefore be tailored in different clinical settings for individual patient. Targeting of the abnormal angiogenesis process is the first significant clinical breakthrough which revolutionized the treatment of advanced ovarian cancer, followed by the advent of poly-(ADP)-ribose polymerase (PARP) inhibitors. These two strategies represented by bevacizumab and olaparib respectively underwent tests of numerous clinical trials. In recent years, immune checkpoint inhibitors (ICIs) have been incorporated into the blueprint of ovarian cancer treatment though the effectiveness still left much to be desired. Herein, we systematically outlined recent advances in targeted therapy for ovarian cancer and summarized the landmark clinical trials for each targeted therapy including angiogenesis inhibitors, PARP inhibitors and ICIs.
Close